Page 2 - Nasdaq Fold News Today

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link. Amicus Therapeutics (NASDAQ:FOLD – Get […]

First Republic Investment Management Inc. boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 9.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,358 shares of the biopharmaceutical company’s stock after purchasing an additional 1,084 shares during the quarter. First Republic […]

Amicus Therapeutics (NASDAQ:FOLD – Free Report) had its target price lowered by Morgan Stanley from $15.00 to $14.00 in a research note issued to investors on Tuesday, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock. FOLD has been the subject of a number of other reports. Bank of […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) was the target of unusually large options trading on Friday. Traders acquired 20,239 call options on the stock. This is an increase of approximately 3,900% compared to the average daily volume of 506 call options. Insider Buying and Selling In related news, Chairman John F. Crowley sold […]

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) had its target price upped by research analysts at JPMorgan Chase & Co. from $17.00 to $19.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside […]

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...

StockNews.com cut shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a buy rating to a hold rating in a research report report published on Friday morning. Amicus Therapeutics Price Performance NASDAQ:FOLD opened at $12.92 on Friday. The stock has a market capitalization of $3.71 billion, a PE ratio of -20.19 and a beta of […]

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...

Panagora Asset Management Inc. boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 9.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,366,965 shares of the biopharmaceutical company’s stock after purchasing an additional 123,604 shares during the quarter. Panagora Asset Management Inc.’s holdings in Amicus Therapeutics were worth […]

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a hold rating to a buy rating in a report published on Thursday. Amicus Therapeutics Trading Up 1.4 % FOLD stock opened at $12.86 on Thursday. The company has a quick ratio of 2.40, a current ratio of 2.72 and a debt-to-equity ratio of […]